BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17675154)

  • 1. The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes.
    Lorand-Metze I; Califani SM; Ribeiro E; Lima CS; Metze K
    Leuk Res; 2008 Feb; 32(2):211-3. PubMed ID: 17675154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
    Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
    Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
    Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
    J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.
    Ribeiro E; Matarraz Sudón S; de Santiago M; Lima CS; Metze K; Giralt M; Saad ST; de Matos AO; Lorand-Metze I
    Leuk Res; 2006 Jan; 30(1):9-16. PubMed ID: 16005514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic quantitative features of patients with acute myeloid leukemia.
    Pereira FG; Metze K; Costa FP; Lima CS; Lorand-Metze I
    Neoplasma; 2006; 53(2):155-60. PubMed ID: 16575472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders.
    Lorand-Metze I; Ribeiro E; Lima CS; Batista LS; Metze K
    Leuk Res; 2007 Feb; 31(2):147-55. PubMed ID: 16750852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors.
    Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores J; Bárcena P; Rasillo A; Sayagues JM; Sánchez ML; Hernandez-Campo P; Hernandez Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Orfao A
    Leukemia; 2008 Jun; 22(6):1175-83. PubMed ID: 18337765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes.
    Maftoun-Banankhah S; Maleki A; Karandikar NJ; Arbini AA; Fuda FS; Wang HY; Chen W
    Am J Clin Pathol; 2008 Feb; 129(2):300-8. PubMed ID: 18208811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis.
    Karmon Y; Manaster J; Chezar J
    Cytometry; 2002 Aug; 50(4):225-30. PubMed ID: 12210602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface marker abnormalities in myelodysplastic syndromes.
    Elghetany MT
    Haematologica; 1998 Dec; 83(12):1104-15. PubMed ID: 9949628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
    Falco P; Levis A; Stacchini A; Ciriello MM; Geuna M; Notari P; Omedè P; Pautasso M; Prato G; Strola G; Gioia D; Bonferroni M; Cametti G; Ferrero D; Freilone R; Gaidano G; Marinone C; Marmont F; Pollio B; Salvi F; Saglio G; Girotto M;
    Eur J Haematol; 2011 Nov; 87(5):409-18. PubMed ID: 21711395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
    Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
    Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.
    Flores-Figueroa E; Arana-Trejo RM; Gutiérrez-Espíndola G; Pérez-Cabrera A; Mayani H
    Leuk Res; 2005 Feb; 29(2):215-24. PubMed ID: 15607371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
    Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
    Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.
    Reis-Alves SC; Traina F; Harada G; Campos PM; Saad ST; Metze K; Lorand-Metze I
    PLoS One; 2013; 8(12):e81048. PubMed ID: 24324660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.